We are live on
!
Find out more
SC
Stralem & Co Portfolio holdings
AUM
$157M
1-Year Est. Return
4.29%
This Fund
S&P 500
This Quarter
Est. Return
+7.38%
1 Year Est. Return
+4.29%
3 Year Est. Return
+25.48%
5 Year Est. Return
+55.56%
10 Year Est. Return
–
AUM
$855M
AUM Growth
+$14.9M
(+1.8%)
Cap. Flow
-$40.9M
Cap. Flow
% of AUM
-4.79%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
54
New
–
Increased
–
Reduced
36
Closed
6
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$2.14M |
| 2 |
DuPont de Nemours
DD
|
+$2.13M |
| 3 |
Adobe
ADBE
|
+$2.08M |
| 4 |
UnitedHealth
UNH
|
+$1.98M |
| 5 |
Oracle
ORCL
|
+$1.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.48% |
| 2 | Communication Services | 12.77% |
| 3 | Technology | 10.32% |
| 4 | Consumer Staples | 9.52% |
| 5 | Utilities | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CVS Health
CVS
$121B
| $21.1M | 2.46% |
268,170
-3,900
| -1% | -$311K |
|
27
Chubb
CB
$132B
| $18.3M | 2.14% |
134,445
-6,230
| -4% | -$838K |
|
28
EOG Resources
EOG
$75.1B
| $17.8M | 2.08% |
182,180
-6,550
| -3% | -$653K |
|
29
Johnson & Johnson
JNJ
$629B
| $17.7M | 2.07% |
142,180
-5,470
| -4% | -$653K |
|
|
CELG
30
DELISTED
Celgene Corp
CELG
| $17.3M | 2.02% |
138,915
-10,759
| -7% | -$1.29M |
|
31
Abbott
ABT
$192B
| $16.8M | 1.96% |
377,355
-21,955
| -5% | -$949K |
|
32
Amgen
AMGN
$225B
| $16.7M | 1.96% |
102,015
-5,855
| -5% | -$973K |
|
33
Thermo Fisher Scientific
TMO
$223B
| $16.7M | 1.95% |
108,765
-9,420
| -8% | -$1.44M |
|
34
Chevron
CVX
$386B
| $16.5M | 1.93% |
153,845
-6,795
| -4% | -$762K |
|
35
ExxonMobil
XOM
$657B
| $15.6M | 1.83% |
190,370
-6,803
| -3% | -$568K |
|
36
Bristol-Myers Squibb
BMY
$130B
| $2.45M | 0.29% |
45,100
| – | – |
|
37
Coca-Cola
KO
$373B
| $1.62M | 0.19% |
38,100
-12,000
| -24% | -$501K |
|
38
Automatic Data Processing
ADP
$107B
| $1.32M | 0.15% |
12,900
| – | – |
|
39
Apple
AAPL
$4.41T
| $1.18M | 0.14% |
32,800
| – | – |
|
40
Eli Lilly
LLY
$1.09T
| $1.06M | 0.12% |
12,600
| – | – |
|
41
FirstEnergy
FE
$27.2B
| $1.03M | 0.12% |
32,500
| – | – |
|
42
Agilent Technologies
A
$41.9B
| $946K | 0.11% |
17,900
| – | – |
|
43
Costco
COST
$421B
| $939K | 0.11% |
5,600
| – | – |
|
44
Colgate-Palmolive
CL
$73.6B
| $930K | 0.11% |
12,700
| – | – |
|
45
International Flavors & Fragrances
IFF
$21.4B
| $861K | 0.1% |
6,500
| – | – |
|
46
Zimmer Biomet
ZBH
$18.7B
| $818K | 0.1% |
6,901
| – | – |
|
47
Gilead Sciences
GILD
$168B
| $652K | 0.08% |
9,600
| – | – |
|
48
Archer Daniels Midland
ADM
$38.4B
| $216K | 0.03% |
4,700
| – | – |
|
49
AbbVie
ABBV
$440B
| – | – |
-6,500
| Closed | -$407K |
|
50
Berkshire Hathaway Class B
BRK.B
$1.09T
| – | – |
-7,500
| Closed | -$1.22M |
|
Similar funds
LI
BC
JT
SCM
HF
SMFS
CCM
CCM
Stralem & Co's Q1 2017 Portfolio in Review
As of Q1 2017, Stralem & Co held 54 positions worth $855M, up 1.8% from $840M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Stralem & Co withdrew a net $40.9M in Q1 2017, closing 6 positions and reducing 36 holdings. Its most notable exit was Berkshire Hathaway Class B, an estimated $1.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier, followed by Communication Services and Technology.
- Stralem & Co's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $2.14M.
- Stralem & Co fully exited Berkshire Hathaway Class B in Q1 2017, selling an estimated $1.22M.
- Stralem & Co's ten largest holdings make up 33% of its $855M portfolio in Q1 2017.
- Stralem & Co opened 0 new positions and closed 6 in Q1 2017.
- Stralem & Co's portfolio value rose 1.8% quarter-over-quarter to $855M.
Based on Stralem & Co's 13F filing for Q1 2017, filed 18 Apr 2017.